Learning the Maximum Tolerated Dose for Continuous Toxicity via Monotone Bayesian Trees
summary
The gist
Phase I cancer trials aim to determine the maximum tolerated dose (MTD) while minimizing patient toxicity risks, utilizing continuous toxicity measurements.
In short
Phase I cancer trials use Bayesian additive regression trees (iBART and mBART) to find the maximum tolerated dose (MTD) for continuously measured toxicity. The study compared three dose-finding methods against seven different toxicity curve shapes, showing that tree models performed strongly in predicting toxicity counts and errors. Flexible MTD estimation is practical without needing to know the exact shape of the dose-toxicity curve.
Key concepts
- Bayesian Additive Regression Trees (BART)
- These are statistical models used to predict continuous outcomes, like toxicity levels. They work by building a collection of decision trees that combine predictions from individual trees. In this study, two specialized versions were used: isotonic BART (iBART) and monotone BART (mBART), which help control the shape of the predicted results.
- Maximum Tolerated Dose (MTD)
- The MTD is the highest dose a patient can safely receive without experiencing unacceptable toxicity. The study aimed to find this value using continuous measurements of toxicity. They used these models to guide dose escalation, ensuring patients received a safe and effective dose while minimizing harm.
- Isotonic BART (iBART) and Monotone BART (mBART)
- These are two specific types of Bayesian trees used for modeling toxicity curves. iBART projects predictions onto nondecreasing functions, meaning the predicted toxicity levels will always increase as the dose increases. mBART constrains the model itself to ensure it remains monotone, which is crucial when modeling dose-response relationships.
- Dose-Limiting Toxicity (DLT) and EWOC
- DLT refers to toxicity that limits a patient's ability to continue treatment. The study used a cumulative DLT stopping rule: enrollment ends if the DLT count exceeds four or 45 patients are observed. This decision-making process, combined with an escalation strategy called Overdose Control with Escalation (EWOC), helps determine the final safe dose.
Terminology used across episodes
This episode discusses
- Learning the Maximum Tolerated Dose for Continuous Toxicity via Monotone Bayesian Trees · Paper Radio
- Approximate Dynamic Programming and Its Applications to the Design of Phase I Cancer Trials
- Incorporating Individual and Collective Ethics into Phase I Cancer Trial Designs
- Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials
The paper
Learning the Maximum Tolerated Dose for Continuous Toxicity via Monotone Bayesian Trees · Read on arXiv
Phase I cancer trials seek the maximum tolerated dose (MTD) while protecting patients from excessive toxicity. Dose assignments must therefore balance patient safety with learning the dose--toxicity relationship as data accrue. We model continuously measured toxicity outcomes using two forms of Bayesian additive regression trees (BART): isotonic BART projects posterior response curves onto nondecreasing functions, whereas monotone BART constrains the model. Joint curve and variance draws induce an MTD posterior that guides dose selection through escalation with overdose control (EWOC). We compare these methods with three parametric procedures across seven dose--toxicity curves in simulation. We assess dose-limiting toxicity (DLT) counts, above-MTD assignments, signed last-dose error, and relative absolute error. The tree procedures attained the lowest mean RAE on four nonlinear curves and jointly minimized mean DLT counts and above-MTD assignments on four curves. A Bayesian reinforcement learning perspective formulates these sequential decisions as a finite-horizon planning problem. Dose restrictions yield a lower bound on last-dose error; under exact posterior-predictive evaluation, an EWOC-based rollout policy has no greater expected weighted loss than its baseline. Dose Trial Lab, a desktop simulator for all five procedures, accompanies the supplementary material.
Transcript
Introduction to the show: ident: Statistics. The day in statistics: methods, theory and the inference under them.
Tom: We're looking at the paper: "Learning the Maximum Tolerated Dose for Continuous Toxicity via Monotone Bayesian Trees".
Jane: Here's the gist of the paper. Phase I cancer trials aim to determine the maximum tolerated dose (MTD) while minimizing patient toxicity risks, utilizing continuous toxicity measurements.
Tom: The study employs two forms of Bayesian additive regression trees: isotonic BART (iBART), which projects posterior response curves onto nondecreasing functions, and monotone BART (mBART), which constrains the model itself.
Jane: These methods are used to model continuously measured toxicity outcomes within a Bayesian framework to guide dose selection through escalation with overdose control (EWOC).
Tom: The analysis compares three parametric procedures: one-parameter linear dose finder (1PLD), two-parameter linear dose finder (2PLD), and three-parameter nonlinear dose finder (3PND).
Paper summary: Tom: So we're looking at a paper called "Learning the Maximum Tolerated Dose for Continuous Toxicity via Monotone Bayesian Trees." This study looks at how to find the maximum tolerated dose while trying to keep patient toxicity risks low as more data comes in.
Jane: Exactly. The main idea is that they use these Bayesian additive regression trees, specifically two versions of them, called isotonic BART and monotone BART, to model those continuously measured toxicity outcomes. They're trying to figure out the MTD as the data accumulates.
Lu: What's really interesting is that they don't just pick one method; they compare these tree procedures against three different ways of finding a dose across seven different kinds of dose-toxicity curves in simulation, like linear or exponential ones.
Meng: So, what does this mean for someone who is actually trying to run a trial? Is this just theoretical math that won't work when the data gets messy?
Lalam: Well, the paper shows that these tree procedures do something pretty strong; isotonic BART did the best job minimizing the observed mean dose-limiting toxicity counts and above-MTD assignments on four of those seven curves.
Tom: That's a big win for iBART, but I want to know about precision too. How accurate are we when we actually pick a dose? Does it just give us a good guess or is the error small enough for real patient decisions?
Jane: They also looked at precision using signed last-dose error and relative absolute error, and they found that the one-parameter linear dose finder performed best on the linear curve, and three parameter nonlinear dose finder did well on the quadratic and square root curves.
Lu: The paper also explores a way to make decisions sequentially under a Bayesian reinforcement learning view, which sets a lower bound on how much error you can expect for that last dose estimate.
Meng: A lower bound is good, but what about the actual trial rollout? If you're actually running this in the field, how does this change your daily decision-making compared to just using an escalation with overdose control strategy?
Lalam: They found that under exact posterior predictive evaluation, a rollout policy based on an overdose control strategy performed no better than the baseline strategy for expected weighted loss.
Tom: So it sounds like the theoretical setup is solid, and even when you look at sequential decision-making under those specific conditions, the rollout policy isn't worse than what we already do. What about how much improvement we actually see in practice?
Jane: They did show that rollout attained lower observed mean weighted loss than overdose control across every single loss profile and planning budget, with reductions ranging from four point one percent to twenty-five point nine percent.
Paper summary: Lu: That range of reduction sounds significant when you think about how much you can shave off the cost or risk in a real trial setting. The paper also concludes that flexible MTD estimation works even in small-sample settings without needing to pre-specify the shape of the dose-toxicity curve.
Meng: I'm skeptical about that claim about small sample sizes; my models break when you have real traffic noise, not just clean simulated data. What happens if the true toxicity curve is really complex and we only have a few patients?
Tom: That's where the paper gets its nuance; it says they established MTD posterior consistency under the condition of a fixed-cell Gaussian model and prior support at the truth. They are making claims based on specific assumptions about what those models look like.
Jane: And they did have a separate comparison using an O6-benzylguanine example, which used a pharmacodynamic response instead of clinical toxicity, to explore different models like 1PLD and two tree models <ref:2609.30190#pg1>.
Lu: That comparison showed that while those methods assign terminal doses in the eighty to one hundred milligrams per square meter region consistent with earlier analyses, they can't compute metrics like above-MTD assignments or relative absolute error against a known target because the true boundary is unknown.
Meng: So, even when using different response types, if you don't know the actual toxicity limit beforehand, you can't really measure how far off your estimate is from the truth. That’s a big limitation for deployment.
Tom: It seems like these methods are very useful for setting up the initial dose selection process and guiding escalation with overdose control, even if we have to be careful about what we assume about the underlying curve shape.
Jane: The title of this paper, "Learning the Maximum Tolerated Dose for Continuous Toxicity via Monotone Bayesian Trees," really captures that balance between learning a limit and managing risk over time.
Lu: It's less about finding one perfect number and more about building a flexible framework that adapts as you gather more data on continuous toxicity outcomes.
Meng: For production deployment, the focus has to be on what breaks when things aren't perfectly Gaussian or when the true boundary is just not known. We need methods that can handle that uncertainty without requiring us to know the exact shape of everything upfront.
Lalam: The paper suggests that flexible MTD estimation remains practical in small sample settings because it doesn't require prespecification of the curve shape, which is a key part of how these tree procedures operate.
Tom: So, while iBART looks strong on the simulated curves for minimizing toxicity counts and above-MTD assignments, we have to keep an eye on those precision metrics like signed last-dose error.
Jane: Right. And remember that the analysis is done under specific model assumptions, so when translating this to a real trial with unknown dynamics, we have to consider those constraints carefully.
Conclusion: Tom: So we've been looking at how these monotone trees help us find the maximum tolerated dose when toxicity measurements are continuous and keep tracking them over time.
Jane: Right, so they’re using these Bayesian trees to model those toxicity outcomes—like how bad a side effect is—as the data comes in, trying to figure out the safest dose.
Lu: Basically, they're using this method to guide dose escalation with overdose control while minimizing patient risk by looking at where the uncertainty falls.
Meng: So what’s the actual result? Does this mean we can just pick one number and be done with it for a trial?
Lalam: The main thing is that these tree procedures do a strong job of finding the maximum tolerated dose across different types of curves, even when you don't know the exact shape of that curve beforehand.
Tom: It sounds like they’ve built a flexible way to handle uncertainty in dosing decisions.
Jane: They did compare different methods, like linear finders and these tree models, on seven totally different kinds of toxicity shapes.
Lu: The paper shows that the monotone BART method tied with isotonic BART for one of those piecewise linear curves, while other methods were better for other curve types.
Meng: I’m still thinking about how this works in a real trial setting where you have to make a quick decision about the next dose.
Tom: Well, they also looked at sequential decision making under a Bayesian view, and they found that the rollout policy actually performed as well as the standard overdose control strategy in terms of expected weighted loss.
Jane: That's interesting because it suggests this isn't just some theoretical setup; it’s practical for how we manage patients during a trial rollout.
Lu: They conclude that flexible maximum tolerated dose estimation is practical even when you don't know the exact shape of the toxicity curve from day one.
Tom: It seems like this opens up a new way to think about how we find safety limits in complex dosing scenarios.
More episodes
- Daily Summary for 2026-11-19
- 2310.07973-Statistical Performance Guarantee for Subgroup Identification with Generic Machine Learning
- 2408.09155-Learning Robust Treatment Rules for Censored Data
- Daily Summary for 2026-11-19
- 2603.23397-Kinetic Langevin Splitting Schemes for Constrained Sampling
- 2606.09906-An information-geometric framework for mapping maximum potential biodiversity
- 2603.27718-Induced replication and the assessment of models
- 1307.0898-Entropy of a Zipfian Distributed Lexicon
- 2406.19974-Generalizing self-normalized importance sampling with couplings
- 2412.10213-Collaborative Optimal Design of Controlled Experiments with Subject Covariates